Lipid Parameters Including Lipoprotein (A) in Patients Undergoing CAPD and Hemodialysis

Abstract

Objective

Oyslipidemia possibly contributes to the vascular complications commonly afflicting uremic patients. Lipoprotein (a) [Lp(a)] has been identified as an independent risk factor for atherosclerotic vascular dis ease. The aim of our study was to compare lipidparameters, including Lp(a), between hemodialysis (HO) and continuous ambulatory peritoneal dialysis (CAPO) patients.

Design

A cross-sectional study.

Setting

University Medical Center.

Participants

Forty CAPO and 40 HO patients carefully matched for age, sex, body mass index (BMI), smoking habits, and duration of dialysis were studied. A group of 40 healthy individuals matched for age, sex, BMI, and smoking habits was used as control.

Interventions

None.

Main Outcome Measures

Serum lipid parameters and atherogenic risk ratios were the main outcome measures.

Results

Both groups of dialysis patients had increased serum triglycerides and decreased levels of Apo AI and HOL cholesterol compared to controls. Moreover, the risk ratios total cholesterol/HOL cholesterol and LOL cholesterol/HOL cholesterol were significantly higher, and the ratio ApoA1/ApoB was significantly lower in both groups of patients in comparison to the normal subjects. Both groups of dialysis patients exhibited decreased ratios of LOL cholesterol/ApoB and HOL cholesterol/ApoAI, suggesting the presence of compositional lipoprotein changes. CAPO patients had a more atherogenic lipid profile compared to HO patients, since they exhibited higher levels of total and LOL cholesterol, of ApoB as well as of the ratios total cholesterol/HOL cholesterol and LOL cholesterol/ HOL cholesterol, and lower levels of the ratio ApoA1/ApoB compared to HO patients. Both groups of dialysis patients had increased serum Lp(a) levels. Even though CAPO patients had higher serum Lp(a) levels than HO patients, the differences between these two groups were only marginally statistically significant (p = 0.056 by Mann-Whitney U-test). Uremic dyslipidemia was positively correlated with serum albumin levels in both groups of patients.

Conclusion

CAPO patients exhibit a more atherogenic lipid profile than that of HO patients. The marked disturbances in Lp(a) levels may further increase the vascular risk in both groups of patients.

Keywords

Hemodialysis lipoprotein (a)lipid parameters atherogenesis

Get full access to this article

View all access options for this article.

References

Churchill

D.N.

, Taylor

, Cook

R.J.

Canadian hemodialysis morbidity study.

Am J Kidney Dis 1992; 19: 214–34.

Raine AEG, The EDTA Registry Committee.

Combined report on regular dialysis and transplantation in Europe, XXII, 1991.

Nephrol Dial Transplant 1992; 2: 7–35.

US Renal Data System (USRDS) 1991, Annual Data Report. Survival probabilities and causes of death. Bethesda, MD, NIH, NIDDK, 1991: 31–40.

K.W.

, Greene

E.L.

, Raij

Cardiovascular risk factors in chronic renal failure and hemodialysis populations.

Am J Kidney Dis 1992; 19: 505–13.

Hahn

, Oette

, Mondorf

, Finke

, Sieberth

H.G.

Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to hyperlipoproteinemias.

Atherosclerosis 1983; 48: 279–88.

Berg

A new serum type system in man -the Lp system.

Acta Pathol Microbiol Scand 1963; 59: 369–82.

Utermann

The mysteries of lipoprotein (a).

Science 1989; 246: 904–10.

Durrington

P.N.

, Ishola

, Hunt

, Arrol

, Bhatnagar

Apolipoprotein (a), Al and B and parental history in men with early onset ischemic heart disease.

Lancet 1988; I: 1070–3.

Armstrong

V.W.

, Cremer

, Eberle

The association between serum Lp(a) concentration and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels.

Atherosclerosis 1986; 62: 249–57.

10.

Dahlen

G.H.

, Guy ton

J.R.

, Altar

M.D.

, Farmer

J.A.

, Kautz

J.A.

, Got to

A.M.

Association of levels oflipoprotein Lp(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography.

Circulation 1986; 74: 758–65.

11.

Elisaf

, Bairaktari

, Tziallas

Lipid parameters including Lp(a) in hemodialysis patients.

Ren Fail 1994; 16(4): 501–9.

12.

Kandoussi

, Cachera

, Pagniez

, Dracon

, Fruchart

J.C.

, Tacquet

Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD.

Kidney Int 1992; 42: 424–5.

13.

Buggy

, Breathnach

, Keogh

, Cooke

, Feely

Lipoprotein (a) and treatment of chronic renal disease.

J Intern Med 1993; 234: 453–5.

14.

Murphy

B.G.

, McNamee

, Duly

, Henry

, Archbold

, Trinick

Increased serum apolipoprotein (a) in patients with chronic renal failure with continuous ambulatory peritoneal dialysis.

Atherosclerosis 1992; 92: 53–7.

15.

Barbagallo

C.M.

, Averna

M.R.

, Sparacino

Lipoprotein (a) levels in end-stage renal failure and renal transplantation.

Nephron 1993; 64: 560–4.

16.

Wanner

, Lubrich-Birkner

, Summ

, Wieland

, Schollmeyer

Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients.

Nephron 1992; 62: 40–6.

17.

Webb

A.T.

, Reaveley

D.A.

, O'Donnell

, O'Connor

, Seed

, Brown

E.A.

Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis.

Nephrol Dial Transplant 1993; 8: 609–13.

18.

Anwar

, Bhatnagar

, Short

C.D.

, Mackness

M.I.

, Durrington

P.N.

, Prais

Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis.

Nephrol Dial Transplant 1993; 8: 71–4.

19.

Goldwasser

, Michel

M-A

, Collier

Prealbumin and lipoprotein (a) in hemodialysis: relationships with patient and vascular access survival.

Am J Kidney Dis 1993; 22: 215–25.

20.

Okura

, Saku

, Hirata

Serum lipoprotein (a) levels in maintenance haemodialysis patients.

Nephron 1993; 65: 46–50.

21.

Parsy

, Dracon

, Cachera

Lipoprotein abnormalities in chronic haemodialysis patients.

Nephrol Dial Transplant 1988; 3: 51–6.

22.

Pelegri

, Romero

, Senti

, Nogues

, Pedro-Botet

, Rubies-Prat

Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.

Nephrol Dial Transplant 1992; 7: 623–6.

23.

Parra

H.J.

, Mezdour

, Cachera

, Dracon

, Tacquet

, Fruchart

J.C.

Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis.

Clin Chem 1987; 33: 721.

24.

Barbagallo

C.M.

, Averna

M.R.

, Scafidi

, Galione

, Notarbartolo

Increased lipoprotein (a) levels in subjects with chronic renal failure on hemodialysis.

Nephron 1992; 62: 471–2.

25.

Cressman

M.D.

, Heyka

R.J.

, Paganini

E.P.

, O'Neile

, Skibinski

C.I.

, Hoff

H.F.

Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients.

Circulation 1992; 86: 475–82.

26.

Heimann

, Josephson

M.A.

, Fellner

S.K.

, Thistlethwaite

J.R.

, Stuart

F.P.

, Dasgupta

Elevated lipoprotein (a) levels in renal transplantation and hemodialysis patients.

Am J Nephrol 1991; 11: 470–4.

27.

Thillet

, Faucher

, Issad

, Allouache

, Chapman

, Jacobs

Lipoprotein (a) in patients treated by continuous ambulatory peritoneal dialysis.

Am J Kidney Dis 1993; 22: 226–32.

28.

Shoji

, Nishizawa

, Nishitani

, Yamakawa

, Morii

High serum lipoprotein (a) concentrations in uremic patients treated with continuous ambulatory peritoneal dialysis.

Clin Nephrol 1992; 38: 271–6.

29.

Friedewald

W.T.

, Levy

R.I.

, Fredrickson

D.S.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Clin Chem 1972; 18: 409–502.

30.

Silberman

S.R.

, Armentrout

M.A.

, Vella

F.A.

, Saha

A.L.

MACRA (TM) Lp(a) for quantitation of human lipoprotein (a) by enzyme linked immunoassay (Abstract).

Clin Chem 1990; 36: 961.

31.

Chan

M.K.

Lipid metabolism in renal failure.

Clin Biochem 1990; 23: 61–5.

32.

Avram

M.M.

, Fein

P.A.

, Antignani

Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemo dialysis and continuous ambulatory peritoneal dialysis.

Am J Med 1989; 87: 55N–60N.

33.

Avram

M.M.

, Goldwasser

, Burrell

D.E.

, Antignani

, Fein

P.A.

, Mittman

The uremic dyslipidemia: a crosssectional and longitudinal study.

Am J Kidney Dis 1992; 20: 324–35.

34.

Elisaf

, Dardamanis

M.A.

, Papagalanis

N.D.

, Siamopoulos

K.C.

Lipid abnormalities in chronic uremic patients.

Scand J Urol Nephrol 1993; 27: 101–8.

35.

Assman

, Schulte

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (The PROCAM experience).

Am J Cardiol 1992; 70: 733–7.

36.

Kinosian

, Glick

, Garland

Cholesterol and coronary heart disease: predicting risks by levels and ratios.

Ann Intern Med 1994; 121: 641–7.

37.

Gamba

, Mejia

J.L.

, Saldivar

, Pena

J.C.

, Correa Rotter

Death risk in CAPD patients.

Nephron 1993; 63: 23–7.

38.

Austin

M.A.

, King

M.C.

, Vranizan

K.M.

, Krauss

R.M.

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Circulation 1990; 82: 495–506.

39.

Chait

, Brazg

R.L.

, Tribble

D.L.

, Krauss

R.M.

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.

Am J Med 1993; 94: 350–6.

40.

Deckelbaum

R.J.

, Granot

, Oschry

, Rose

, Eisenberg

Plasma triglyceride determines structure-composition in low and high density lipoproteins.

Arteriosclerosis 1984; 4: 225–31.

41.

Cattran

D.C.

, Fenton

S.S.A.

, Wilson

D.R.

, Steiner

Defective triglyceride removal in lipemia associated with peritoneal dialysis and hemodialysis.

Ann Intern Med 1976; 85: 29–33.

42.

Lindholm

, Norbeck

H.E.

Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis

Acta Med Scand 1986; 220: 143–51.

43.

Sniderman

, Cianflone

, Kwiterovich

Jr. , Hutchinson

, Barre

, Prichard

Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis.

Atherosclerosis 1987; 65: 257–64.

44.

Oreopoulos

D.G.

, Khanna

, McCready

Continuous ambulatory peritoneal dialysis in Canada.

Dial Transplant 1980; 9: 224–6.

45.

Kagan

, Bar-Khayim

, Schafer

, Fainaru

Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels.

Kidney Int 1990; 37: 980–90.

46.

Breckenridge

W.C.

, Roncari

D.A.K.

, Khanna

, Oreopoulos

D.G.

The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins.

Atherosclerosis 1982; 45: 249–58.

47.

Heimbürger

, Bergström

, Lindholm

Is serum albumin an index of nutritional status in continuous ambulatory peritoneal dialysis patients?

Perit Dial Int 1994; 14: 108–14.